ARTICLE | Company News

Caliber Biotherapeutics, Mapp Biopharmaceutical, U.S. Department of Health and Human Services infectious news

October 6, 2014 7:00 AM UTC

HHS said it is in talks with biomanufacturing company Caliber to produce Mapp's ZMapp Ebola treatment. HHS said it wants to boost ZMapp production further and noted Caliber has expertise in tobacco plant-based vaccine and therapeutic protein manufacturing. Mapp uses tobacco plants to manufacture the product, which is a combination of three mAbs targeting Ebola glycoproteins GP1 and GP2 in tobacco plants. Caliber could not be reached for details. ...